NCT04289662View on ClinicalTrials.gov

K-924 Phase III Long Term Study

PHASE3CompletedINTERVENTIONAL

Enrollment

110

Participants

Timeline

Start Date

March 23, 2020

Primary Completion Date

August 7, 2021

Study Completion Date

August 7, 2021

Conditions

Hypercholesterolemia

Interventions

DRUG

K-924 LD

Pitavastatin 2 mg / Ezetimibe 10 mg tables

DRUG

K-924 HD

Pitavastatin 4 mg / Ezetimibe 10 mg tables

Trial Locations (13)

Unknown

Chubu Rosai Hospital, Aichi

Daido Clinic, Aichi

Nakamura Cardiovascular Clinic, Fukuoka

Nippon Kokan Fukuyama Hospital, Hiroshima

Hasegawa Medicine Clinic, Hokkaido

Miyanomori Memorial Hospital, Hokkaido

Yuri Ono Clinic, Hokkaido

Ota General Hospital, Kanagawa

Suwa Red Cross Hospital, Nagano

Shiraiwa medical clinic, Osaka

Minamino Cardiovascular Hospital, Tokyo

Tokyo Shinagawa Hospital, Tokyo

Tokyo-Eki Center-building Clinic, Tokyo

All Listed Sponsors

lead

Kowa Company, Ltd.

INDUSTRY

NCT04289662 - K-924 Phase III Long Term Study | Biotech Hunter | Biotech Hunter